Redox Imbalance in CD4+ T Cells of Relapsing-Remitting Multiple Sclerosis Patients. 2020

Mohammad Javad Tavassolifar, and Abdorreza Naser Moghadasi, and Behnaz Esmaeili, and Omid Sadatpour, and Mohammad Vodjgani, and Maryam Izad
Immunology Department, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

As a prevalent autoimmune disease of the central nervous system in young adults, multiple sclerosis (MS) is mediated by T cells, particularly CD4+ subsets. Given the evidence that the perturbation in reactive oxygen species (ROS) production has a pivotal role in the onset and progression of MS, its regulation through the antioxidant molecules is too important. Here, we investigated the level of the redox system components in lymphocytes and CD4+ T cells of MS patients. The study was performed on relapsing-remitting MS (RRMS) patients (n = 29) and age- and sex-matched healthy controls (n = 15). Peripheral blood mononuclear cells (PBMCs) were cultured and stimulated by anti-CD3/CD28. The level of ROS, anion superoxide (O2 -), and L-𝛾-glutamyl-Lcysteinylglycine (GSH) was measured by flow cytometry in lymphocytes/CD4+ T cells. The gene expression level of gp91phox, catalase, superoxide dismutase 1/2 (SOD), and nuclear factor-E2-related factor (Nrf2) was also measured by real-time PCR. We found that lymphocytes/CD4+ T cells of RRMS patients at the relapse phase significantly produced higher levels of ROS and O2 - compared to patients at the remission phase (P value < 0.001) and healthy controls (P value < 0.001 and P value < 0.05, respectively). Interestingly, the gene expression level of gp91phox, known as the catalytic subunit of the NADPH oxidase, significantly increased in MS patients at the relapse phase (P value < 0.05). Furthermore, the catalase expression augmented in patients at the acute phase (P value < 0.05), while an increased expression of SOD1 and Nrf2 was found in RRMS patients at relapse and remission phases (P value < 0.05). The increased production of ROS in CD4+ T cells of RRMS patients highlights the importance of amplifying antioxidant components as an efficient approach to ameliorate disease activity in MS patients.

UI MeSH Term Description Entries
D008297 Male Males
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D005260 Female Females
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013481 Superoxides Highly reactive compounds produced when oxygen is reduced by a single electron. In biological systems, they may be generated during the normal catalytic function of a number of enzymes and during the oxidation of hemoglobin to METHEMOGLOBIN. In living organisms, SUPEROXIDE DISMUTASE protects the cell from the deleterious effects of superoxides. Superoxide Radical,Superoxide,Superoxide Anion

Related Publications

Mohammad Javad Tavassolifar, and Abdorreza Naser Moghadasi, and Behnaz Esmaeili, and Omid Sadatpour, and Mohammad Vodjgani, and Maryam Izad
May 2015, Journal of biotechnology,
Mohammad Javad Tavassolifar, and Abdorreza Naser Moghadasi, and Behnaz Esmaeili, and Omid Sadatpour, and Mohammad Vodjgani, and Maryam Izad
December 2013, Multiple sclerosis (Houndmills, Basingstoke, England),
Mohammad Javad Tavassolifar, and Abdorreza Naser Moghadasi, and Behnaz Esmaeili, and Omid Sadatpour, and Mohammad Vodjgani, and Maryam Izad
August 1988, Annals of neurology,
Mohammad Javad Tavassolifar, and Abdorreza Naser Moghadasi, and Behnaz Esmaeili, and Omid Sadatpour, and Mohammad Vodjgani, and Maryam Izad
January 2011, Journal of the neurological sciences,
Mohammad Javad Tavassolifar, and Abdorreza Naser Moghadasi, and Behnaz Esmaeili, and Omid Sadatpour, and Mohammad Vodjgani, and Maryam Izad
May 2010, Human immunology,
Mohammad Javad Tavassolifar, and Abdorreza Naser Moghadasi, and Behnaz Esmaeili, and Omid Sadatpour, and Mohammad Vodjgani, and Maryam Izad
November 2004, Clinical immunology (Orlando, Fla.),
Mohammad Javad Tavassolifar, and Abdorreza Naser Moghadasi, and Behnaz Esmaeili, and Omid Sadatpour, and Mohammad Vodjgani, and Maryam Izad
January 2022, Frontiers in immunology,
Mohammad Javad Tavassolifar, and Abdorreza Naser Moghadasi, and Behnaz Esmaeili, and Omid Sadatpour, and Mohammad Vodjgani, and Maryam Izad
January 2014, Journal of immunology research,
Mohammad Javad Tavassolifar, and Abdorreza Naser Moghadasi, and Behnaz Esmaeili, and Omid Sadatpour, and Mohammad Vodjgani, and Maryam Izad
May 2021, Brain and nerve = Shinkei kenkyu no shinpo,
Mohammad Javad Tavassolifar, and Abdorreza Naser Moghadasi, and Behnaz Esmaeili, and Omid Sadatpour, and Mohammad Vodjgani, and Maryam Izad
January 2021, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Copied contents to your clipboard!